<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03731260</url>
  </required_header>
  <id_info>
    <org_study_id>BLU-285-2203</org_study_id>
    <secondary_id>2018-000588-99</secondary_id>
    <nct_id>NCT03731260</nct_id>
  </id_info>
  <brief_title>(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis</brief_title>
  <official_title>A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blueprint Medicines Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blueprint Medicines Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy
      and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with
      indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. The
      study will be conducted in 3 parts. All patients will receive treatment with avapritinib
      during Part 3 including those rolling over from the placebo group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In Part 1 of the study, patients will be randomly assigned to 1 of 3 doses of avapritinib or to placebo + BSC. Once the recommended phase 2 dose (RP2D) of avapritinib is identified in Part 1, patients in Part 2 will be randomly assigned to receive avapritinib at the RP2D + BSC or matching placebo + BSC. In Part 3, patients who have completed treatment in Part 1 or Part 2 of the study (including those initially randomized to placebo) may participate in a long-term open-label extension, receiving avapritinib at the RP2D + BSC.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Recommended Phase 2 dose (RP2D) in patients with ISM</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Proportion of responders, defined as ≥30% reduction in ISM Symptom Assessment Form (ISM-SAF) total symptom score (TSS)</measure>
    <time_frame>6 months</time_frame>
    <description>0 - 120 points (higher value represents worse symptom outcomes)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Proportion of patients with a ≥50% reduction in serum tryptase</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Proportion of patients with a ≥50% reduction in peripheral blood V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog aspartate 816 valine (KIT D816V) allele fraction or undetectable for patients with detectable mutation at Baseline</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Mean change in ISM Symptom Assessment Form (ISM-SAF) total symptom score (TSS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Proportion of patients with a ≥50% reduction in bone marrow mast cells or no aggregates for patients with aggregates at Baseline</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum tryptase</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog aspartate 816 valine (KIT D816V) allele burden in blood</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone marrow mast cells</measure>
    <time_frame>Up to 1 year after the end of Part 1 and Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in best supportive care (BSC) concomitant medication usage</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mastocytosis Quality of Life Questionnaire (MC-QoL)</measure>
    <time_frame>Each study visit through Part 3 Cycle 12 (28-day cycles)</time_frame>
    <description>0 - 100 points (higher value represents worse symptom outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient's Global Impression of Symptom Severity (PGIS)</measure>
    <time_frame>Each study visit through Part 3 Cycle 12 (28-day cycles)</time_frame>
    <description>0 - 10 points (higher value represents worse symptom outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 12-item Short Form Health Survey (SF-12)</measure>
    <time_frame>Each study visit through Part 3 Cycle 12 (28-day cycles)</time_frame>
    <description>0 - 100 points (higher value represents better symptom outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patients' Global Impression of Change (PGIC)</measure>
    <time_frame>Each study visit through Part 3 Cycle 12 (28-day cycles)</time_frame>
    <description>1 - 7 (higher value represents worse symptom outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQuol 5 Dimensions 5 Levels (EQ 5D-5L)</measure>
    <time_frame>Each study visit through Part 3 Cycle 12 (28-day cycles)</time_frame>
    <description>0 - 100 (higher value represents better symptom outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of avapritinib as assessed by number of adverse events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>CTCAE version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2 only: Area Under Curve (0 to Tau) for avapritinib</measure>
    <time_frame>Every cycle (28 days) up to Cycle 4 (Part 1) and Cycle 7 (Part 2)</time_frame>
    <description>h•ng/mL</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">244</enrollment>
  <condition>Indolent Systemic Mastocytosis</condition>
  <arm_group>
    <arm_group_label>(Part 1) Avapritinib Dose 1 + BSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avapritinib will be administered orally in continuous 28-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Part 1) Avapritinib Dose 2 + BSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avapritinib will be administered orally in continuous 28-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Part 1) Avapritinib Dose 3 + BSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avapritinib will be administered orally in continuous 28-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Part 1) Placebo + BSC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered orally in continuous 28-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Part 2) Avapritinib RP2D + BSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avapritinib will be administered orally in continuous 28-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Part 2) Placebo + BSC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered orally in continuous 28-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Part 3) Avapritinib RP2D + BSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avapritinib will be administered orally in continuous 28-day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avapritinib</intervention_name>
    <description>Avapritinib tablet</description>
    <arm_group_label>(Part 1) Avapritinib Dose 1 + BSC</arm_group_label>
    <arm_group_label>(Part 1) Avapritinib Dose 2 + BSC</arm_group_label>
    <arm_group_label>(Part 1) Avapritinib Dose 3 + BSC</arm_group_label>
    <arm_group_label>(Part 2) Avapritinib RP2D + BSC</arm_group_label>
    <arm_group_label>(Part 3) Avapritinib RP2D + BSC</arm_group_label>
    <other_name>BLU-285</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>(Part 1) Placebo + BSC</arm_group_label>
    <arm_group_label>(Part 2) Placebo + BSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  1. Patient must have SM, confirmed by Central Pathology Review of BM biopsy, and
             central review of B- and C-findings by WHO diagnostic criteria.

          -  2. Patient must have moderate-to-severe symptoms based on minimum mean total symptom
             score (TSS) of the ISM Symptom Assessment Form (ISM-SAF) over the 14-day eligibility
             screening period.

          -  3. Patient must have failed to achieve adequate symptom control for 1 or more Baseline
             symptoms.

          -  4. For patients receiving corticosteroids, the dose must be ≤ 20 mg/d prednisone or
             equivalent, and the dose must be stable for ≥ 14 days.

          -  5. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status
             (PS) of 0 to 2.

        Key Exclusion Criteria:

          -  1. Patient has been diagnosed with any of the following WHO SM subclassifications:
             cutaneous mastocytosis only, smoldering SM, SM with associated hematologic neoplasm,
             aggressive SM, mast cell leukemia, or mast cell sarcoma.

          -  2. Patient must not have received prior treatment with avapritinib.

          -  3. Patient must not have had any cytoreductive therapy including but not limited to
             masitinib and midostaurin, or investigational agent for &lt; 14 days or 5 half-lives of
             the drug (whichever is longer), and for cladribine, interferon alpha, pegylated
             interferon, or antibody therapy &lt; 28 days or 5 half-lives of the drug (whichever is
             longer), before beginning the 14-day ISM-SAF eligibility TSS assessment.

          -  4. Patient must not have received radiotherapy or psoralen and ultraviolet A (PUVA)
             therapy &lt; 14 days before beginning the 14-day ISM-SAF eligibility TSS assessment.

          -  5. Patient must not have received any hematopoietic growth factor the preceding 14
             days before beginning the 14-day ISM-SAF eligibility TSS assessment.

          -  6. Patient must not have a QT interval corrected using Fridericia's formula (QTcF) of
             &gt; 480 msec.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Blueprint Medicines</last_name>
    <phone>617-714-6707</phone>
    <email>medinfo@blueprintmedicines.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jason Gotlib, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria C. Castells, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel J. DeAngelo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Medicine, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cem Akin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark L. Heaney, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Deininger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vito Sabato, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Vadas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, University of Salerno</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Massimo Triggiani, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata di Verona</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrizia Bonadonna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>J.N.G (Hanneke) Oude Elberink, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paulus Leon Arthur van Daele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>lnstituto de Estudios de Mastocitosis de Castilla la Mancha, Hospital Virgen del Valle - Complejo Hospitalario de Toledo</name>
      <address>
        <city>Toledo</city>
        <zip>45071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Iván Alvarez-Twose, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Deepti H. Radia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://PioneerTrial.com</url>
    <description>More information about the study</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Mastocytosis, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

